Caroline Protin
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Aggressive NK-cell leukaemia: Diverse morphology, distinct clinical features.
Journal: British journal of haematology
Published: November 26, 2024
Ibrutinib-related stellar hematomas of the palms and soles.
Journal: American journal of hematology
Published: October 04, 2024
Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension.
Journal: Journal of hypertension
Published: December 08, 2023
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia.
Journal: Blood advances
Published: February 15, 2022
Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.
Journal: Leukemia & lymphoma
Published: July 13, 2021
Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 12, 2021
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients.
Journal: Leukemia & lymphoma
Published: November 12, 2020
Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: October 26, 2020
Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study.
Journal: Drugs & aging
Published: October 17, 2020
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Journal: American journal of clinical dermatology
Published: July 03, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemia.
Journal: Haematologica
Published: June 10, 2020
Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Journal: Clinical pharmacokinetics
Published: April 25, 2020
Last Updated: 09/26/2026